The impact of JAK1 mutations and MHC-I expression on response to immune checkpoint inhibition in endometrial cancer

Erica Carballo(Vanderbilt University Medical Center), Courtney A. Penn(Vanderbilt University Medical Center), Dandi Huang(Billings Clinic), Julia Wulfkuhle(University of California, San Francisco), Paula I. González-Ericsson(Breast Cancer Research Foundation), Violeta Sánchez(Vanderbilt University), Susan R. Opalenik(Vanderbilt University), Rosa I. Gallagher(George Mason University), James R. Marshall(Roswell Park Comprehensive Cancer Center), Brian D. Lehmann(Vanderbilt University Medical Center), Brandie C. Taylor(Vanderbilt University Medical Center), Katherine Kleinberg(Vanderbilt University Medical Center), B.J. Rimel(Cedars-Sinai Medical Center), Justin M. Balko(Vanderbilt University Medical Center), Andres A. Ocampo(Vanderbilt University Medical Center), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Xiaopeng Sun(Vanderbilt University Medical Center)
Gynecologic Oncology
September 1, 2025
10.1016/j.ygyno.2025.04.075
Cited by 0

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
|The Lancet Oncology|2014|586
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533